Nektar Therapeutics (NKTR) Share-based Compensation (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Share-based Compensation of $3.4 million for Q1 2026, down 13.93% year-over-year from $3.9 million in Q1 2025, and up 52.99% quarter-over-quarter from $2.2 million in Q4 2025.
Nektar Therapeutics (NKTR) Share-based Compensation (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 13.93% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $12.1 million (down 37.95% YoY), while the FY2025 annual figure was $12.6 million, down 41.47% from the prior year.
- Share-based Compensation for Q1 2026 stood at $3.4 million, up from $2.2 million in the prior quarter.
- The five-year high for Share-based Compensation was $21.0 million in Q1 2022, with the low at $2.2 million in Q4 2025.
- The 5-year median for Share-based Compensation is $6.0 million (2024), against an average of $7.5 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation slipped 12.29% in 2022, then sank 54.34% in 2025.
- Nektar Therapeutics' Share-based Compensation stood at $12.7 million in 2022, then slumped by 43.05% to $7.3 million in 2023, then sank by 33.79% to $4.8 million in 2024, then tumbled by 54.34% to $2.2 million in 2025, then surged by 52.99% to $3.4 million in 2026.
- Business Quant data shows NKTR's Share-based Compensation at $3.4 million in Q1 2026, $2.2 million in Q4 2025, and $3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.36 Mn |
| Mar 31, 2026 | 3.36 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 3.07 Mn |
| Sep 30, 2025 | 3.07 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 3.49 Mn |
| Mar 31, 2025 | 3.90 Mn |
| Mar 31, 2025 | 3.90 Mn |
| Dec 31, 2024 | 4.80 Mn |
| Dec 31, 2024 | 4.80 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Jun 30, 2024 | 5.42 Mn |
| Jun 30, 2024 | 5.42 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 7.25 Mn |
| Dec 31, 2023 | 7.25 Mn |